{
  "symbol": "ABBV",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2901,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.033
  },
  "top_positive": [
    {
      "sent": "Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 United States $ 11,106 $ 10,720 3.6 % 3.6 % $ 20,147 $ 19,921 1.1 % 1.1 % International 3,356 3,145 6.8 % 12.7 % 6,625 6,169 7.4 % 12.1 % Net revenues $ 14,462 $ 13,865 4.3 % 5.6 % $ 26,772 $ 26,090 2.6 % 3.7 % 2024 Form 10-Q | 32 The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Immunology Humira United States $ 2,360 $ 3,452 (31.6) % (31.6) % $ 4,131 $ 6,400 (35.5) % (35.5) % International 454 560 (18.9) % (12.5) % 953 1,153 (17.3) % (12.1) % Total $ 2,814 $ 4,012 (29.8) % (28.9) % $ 5,084 $ 7,553 (32.7) % (31.9) % Skyrizi United States $ 2,340 $ 1,634 43.2 % 43.2 % $ 3,996 $ 2,773 44.1 % 44.1 % International 387 249 55.5 % 61.8 % 739 470 57.3 % 61.7 % Total $ 2,727 $ 1,883 44.8 % 45.6 % $ 4,735 $ 3,243 46.0 % 46.6 % Rinvoq United States $ 1,017 $ 645 57.9 % 57.9 % $ 1,742 $ 1,094 59.3 % 59.3 % International 413 273 51.1 % 62.6 % 781 510 53.0 % 62.7 % Total $ 1,430 $ 918 55.8 % 59.2 % $ 2,523 $ 1,604 57.3 % 60.4 % Oncology Imbruvica United States $ 595 $ 666 (10.6) % (10.6) % $ 1,205 $ 1,304 (7.5) % (7.5) % Collaboration revenues 238 241 (1.4) % (1.4) % 466 481 (3.2) % (3.2) % Total $ 833 $ 907 (8.2) % (8.2) % $ 1,671 $ 1,785 (6.4) % (6.4) % Venclexta United States $ 300 $ 265 12.8 % 12.8 % $ 581 $ 530 9.5 % 9.5 % International 337 306 10.4 % 18.4 % 670 579 15.8 % 22.0 % Total $ 637 $ 571 11.5 % 15.8 % $ 1,251 $ 1,109 12.8 % 16.0 % Elahere (a) United States $ 128 $ \u2014 n/m n/m $ 192 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 29 $ \u2014 >100.0 % >100.0 % $ 51 $ \u2014 >100.0 % >100.0 % International 7 \u2014 n/m n/m 12 \u2014 n/m n/m Total $ 36 $ \u2014 >100.0 % >100.0 % $ 63 $ \u2014 >100.0 % >100.0 % Aesthetics Botox Cosmetic United States $ 450 $ 420 7.1 % 7.1 % $ 839 $ 829 1.2 % 1.2 % International 279 265 5.2 % 10.9 % 523 515 1.6 % 6.2 % Total $ 729 $ 685 6.4 % 8.6 % $ 1,362 $ 1,344 1.3 % 3.1 % Juvederm Collection United States $ 138 $ 125 10.4 % 10.4 % $ 244 $ 247 (1.2) % (1.2) % International 205 243 (15.6) % (10.0) % 396 476 (16.8) % (11.9) % Total $ 343 $ 368 (6.8) % (3.1) % $ 640 $ 723 (11.5) % (8.3) % Other Aesthetics United States $ 275 $ 284 (2.3) % (2.3) % $ 556 $ 530 5.2 % 5.2 % International 43 47 (11.7) % (4.1) % 81 87 (8.1) % (1.8) % Total $ 318 $ 331 (3.6) % (2.5) % $ 637 $ 617 3.3 % 4.2 % Neuroscience Botox Therapeutic United States $ 669 $ 614 8.9 % 8.9 % $ 1,280 $ 1,201 6.6 % 6.6 % International 145 134 7.9 % 13.0 % 282 266 5.9 % 9.7 % Total $ 814 $ 748 8.7 % 9.6 % $ 1,562 $ 1,467 6.5 % 7.2 % Vraylar United States $ 773 $ 657 17.5 % 17.5 % $ 1,465 $ 1,217 20.3 % 20.3 % International 1 1 68.8 % 69.2 % 3 2 96.7 % 96.3 % Total $ 774 $ 658 17.6 % 17.6 % $ 1,468 $ 1,219 20.4 % 20.4 % Duodopa United States $ 23 $ 24 (2.6) % (2.6) % $ 48 $ 49 (2.6) % (2.6) % International 90 93 (3.2) % (1.7) % 180 186 (3.0) % (2.8) % Total $ 113 $ 117 (3.1) % (1.9) % $ 228 $ 235 (2.9) % (2.7) % Ubrelvy United States $ 227 $ 194 16.6 % 16.6 % $ 424 $ 344 23.1 % 23.1 % International 4 2 81.6 % 82.3 % 10 4 >100.0 % >100.0 % Total $ 231 $ 196 17.5 % 17.5 % $ 434 $ 348 24.6 % 24.6 % Qulipta United States $ 146 $ 95 52.8 % 52.8 % $ 274 $ 161 69.8 % 69.8 % International 4 1 >100.0 % >100.0 % 7 1 >100.0 % >100.0 % Total $ 150 $ 96 56.3 % 56.3 % $ 281 $ 162 73.2 % 73.2 % 2024 Form 10-Q | 33 Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Other Neuroscience United States $ 57 $ 65 (10.1) % (10.1) % $ 118 $ 140 (14.6) % (14.6) % International 23 5 >100.0 % >100.0 % 36 9 >100.0 % >100.0 % Total $ 80 $ 70 16.6 % 17.5 % $ 154 $ 149 4.1 % 4.7 % Eye Care Ozurdex United States $ 35 $ 34 4.2 % 4.2 % $ 69 $ 73 (5.4) % (5.4) % International 89 85 4.6 % 9.5 % 186 161 15.6 % 18.8 % Total $ 124 $ 119 4.5 % 8.0 % $ 255 $ 234 9.0 % 11.2 % Lumigan/Ganfort United States $ 42 $ 51 (15.8) % (15.8) % $ 71 $ 114 (37.4) % (37.4) % International 61 68 (11.2) % (8.1) % 123 135 (9.4) % (7.3) % Total $ 103 $ 119 (13.2) % (11.4) % $ 194 $ 249 (22.2) % (21.0) % Alphagan/Combigan United States $ 13 $ 32 (59.5) % (59.5) % $ 28 $ 60 (53.4) % (53.4) % International 36 33 9.1 % 20.5 % 80 76 5.0 % 12.8 % Total $ 49 $ 65 (23.7) % (17.8) % $ 108 $ 136 (20.6) % (16.2) % Restasis United States $ 18 $ 82 (77.3) % (77.3) % $ 62 $ 161 (61.0) % (61.0) % International 14 17 (18.9) % (14.5) % 27 30 (11.4) % (6.5) % Total $ 32 $ 99 (67.0) % (66.2) % $ 89 $ 191 (53.1) % (52.3) % Other Eye Care United States $ 131 $ 110 18.9 % 18.9 % $ 236 $ 220 7.1 % 7.1 % International 94 105 (10.1) % (6.1) % 189 195 (2.7) % 1.0 % Total $ 225 $ 215 4.8 % 6.7 % $ 425 $ 415 2.5 % 4.2 % Other Key Products Mavyret United States $ 167 $ 193 (13.2) % (13.2) % $ 311 $ 364 (14.4) % (14.4) % International 202 194 3.8 % 8.8 % 407 387 5.0 % 8.9 % Total $ 369 $ 387 (4.7) % (2.2) % $ 718 $ 751 (4.4) % (2.4) % Creon United States $ 372 $ 282 32.1 % 32.1 % $ 657 $ 587 12.0 % 12.0 % Linzess/Constella United States $ 211 $ 269 (21.7) % (21.7) % $ 468 $ 520 (10.0) % (10.0) % International 10 9 9.1 % 9.2 % 19 17 9.1 % 8.0 % Total $ 221 $ 278 (20.7) % (20.7) % $ 487 $ 537 (9.4) % (9.4) % All other $ 810 $ 741 8.7 % 10.5 % $ 1,554 $ 1,432 8.4 % 10.2 % Total net revenues $ 14,462 $ 13,865 4.3 % 5.6 % $ 26,772 $ 26,090 2.6 % 3.7 % n/m \u2013 Not meaningful (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.",
      "score": 0.9966
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.",
      "score": 0.986
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.",
      "score": 0.986
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders.",
    "ImmunoGen's oncology portfolio includes its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors.",
    "The combination accelerates AbbVie\u2019s entry into the solid tumor space and strengthens its oncology pipeline."
  ]
}